News of Note—Lonza adds API lines for AstraZeneca; Biocon gets EU OK

stock market prices
(Pixabay)

> Lonza is adding two lines at its site in Visp, Switzerland, for production of highly potent APIs as part of a supply deal with AstraZeneca. Release

> Indian biosimilar maker Biocon says its biologics drug product facility and its drug substance facility in Bengaluru were approved by the European Medicines Agency following a March inspection. Release

> AptarGroup in Crystal Lake, Illinois, is spending about $50 million to buy pharmaceutical services companies Nanopharm and Gateway Analytical to expand its offerings to the biopharma industry. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> The Medicines and Healthcare products Regulatory Agency in the U.K. is recalling two batches of 500 mg paracetamol tablets produced by M&A Pharmachem because of discoloration caused by fungi. Stor

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.